News articles about Aduro BioTech (NASDAQ:ADRO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aduro BioTech earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.4326166066319 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Aduro BioTech (ADRO) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
- Aduro BioTech Inc (ADRO) Expected to Announce Quarterly Sales of $3.88 Million (americanbankingnews.com)
- Aduro BioTech (ADRO) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Aduro BioTech (ADRO) Stock Rating Lowered by BidaskClub (americanbankingnews.com)
- Zacks: Analysts Expect Aduro BioTech Inc (ADRO) to Post -$0.30 Earnings Per Share (americanbankingnews.com)
Shares of NASDAQ ADRO traded up $0.15 during mid-day trading on Tuesday, hitting $7.65. The company had a trading volume of 104,673 shares, compared to its average volume of 598,149. The stock has a market cap of $583.25, a P/E ratio of -5.38 and a beta of 2.03. Aduro BioTech has a 1-year low of $5.82 and a 1-year high of $14.05.
A number of research firms have commented on ADRO. BidaskClub cut Aduro BioTech from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 6th. ValuEngine cut Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Friday, April 6th. Zacks Investment Research cut Aduro BioTech from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price target on shares of Aduro BioTech in a research note on Monday, March 5th. Finally, Bank of America decreased their price target on Aduro BioTech from $9.00 to $8.00 and set an “underperform” rating on the stock in a research note on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Aduro BioTech currently has a consensus rating of “Buy” and a consensus target price of $14.50.
In other news, insider Elsas Andrea Van sold 6,874 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.48, for a total value of $44,543.52. Following the sale, the insider now directly owns 216,669 shares in the company, valued at $1,404,015.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Stephen T. Isaacs sold 40,000 shares of the stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $8.91, for a total value of $356,400.00. Following the completion of the sale, the insider now owns 245,746 shares in the company, valued at $2,189,596.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 118,925 shares of company stock worth $1,011,936. Insiders own 6.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Aduro BioTech (ADRO) Stock Price” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2018/04/17/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-aduro-biotech-adro-stock-price.html.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.